Table 1.

Baseline demographic and characteristics of participants.

VariablesParticipants, n = 125
Age, yrs46.5 ± 10.1
Body height, m1.56 ± 0.06
Body weight, kg53.7 ± 9.0
Body mass index, kg/m222.1 ± 3.5
Postmenopausal, no. (%)79 (63.2)
  Age of menopause, yrs45 (41, 49)
  Duration of menopause, yrs5.7 (2.2, 9.8)
Current drinker, no. (%)0
Current smoker, no. (%)2 (1.6)
History of fragility fracture, no. (%)6 (4.8)
Disease duration, yrs10.4 (5.4, 16.0)
SELENA-SLEDAI score1 (0, 3.5)
SDI score1 (0, 1)
Lupus nephritis, no. (%)76 (61.3)
25[OH]D, μg/l17.9 (14.2, 21.3)
Baseline BMD, g/cm2
  Femoral neck0.668 ± 0.105
  Total hip0.802 ± 0.128
  Lumbar spine0.866 ± 0.149
  • Results are mean ± SD or median (interquartile range) unless otherwise indicated. SELENA-SLEDAI: the Safety of Estrogens in Lupus Erythematosus, National Assessment version of the SLE Disease Activity Index; SDI: the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index; 25[OH]D: 25-hydroxy Vitamin D; BMD: bone mineral density.